Physician profile

George Georges

Endocrinology, Diabetes & Metabolism · Richmond, VA

NPI 1700173481

$856.91

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $116.00 2019
Shire North American Group INC $95.50 2019
Lilly USA, LLC $78.97 2019
Abbott Laboratories $66.62 2019
Amgen INC. $60.85 2019
Janssen Pharmaceuticals, INC $56.60 2019
Astrazeneca Pharmaceuticals LP $49.14 2019
Sanofi-Aventis U.S. LLC $36.28 2019
Valeritas, INC. $35.36 2019
Pfizer INC. $29.12 2019
Becton, Dickinson and Company $24.20 2019
Merck Sharp & Dohme LLC $23.52 2019
Ibsa Pharma INC. $18.34 2019
Tandem Diabetes Care, INC. $17.83 2019
Abbvie INC. $16.32 2019
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $16.27 2019
Dexcom, INC. $15.89 2019
Medtronic Minimed, INC. $15.72 2019
Corcept Therapeutics $15.65 2019
Amarin Pharma, INC. $15.26 2019
Aytu Biopharma, INC. $14.60 2019
Antares Pharma, INC. $14.31 2019
Insulet Corporation $12.91 2019
Amneal Pharmaceuticals LLC $11.65 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George Georges

$856.91

in general payments reported 2019-2025

Years
2019
Top company
Novo Nordisk INC

https://glasscript.com/doctor/1384969/george-georges

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.